Vicriviroc + MK2048 + Progestin Vaginal Ring
Description: A vaginal ring whose mechanism of action is CCR5 inhibitor, integrase inhibitor and a progestin for protection against HIV and pregnancy.
Product Details
Active Pharmaceutical Ingredient (API):
Inactive material: EVA
Status Details
Status Details: - Phase I study of 2-ARV IVR prototype completed in 2016.
- Merck announced that it would discontinue development of its investigational CCR5 antagonist vicriviroc for the treatment of HIV infection in both treatment-naive and treatment-experienced patients, due to unimpressive results in clinical trials.